Cheshire & Merseyside

Ì



Cancer Alliance # the patient must not have had progressive disease during venetoclax and objoutuzumab/ rituximab # the patient must not have had progressive disease during venetoclax and objoutuzumab/ rituximab

Treatment for Relapsed/ Refractory CLL

